Oral Contraceptives Petition Seeking Ban On Third-Generation Products Denied By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Public Citizen losses again as the agency says current product labeling for desogestrel-containing oral contraceptives adequately describes the risk of venous thromboembolism; FDA notes the difficulty in comparing the magnitude of risks between combination OCs.